Systemic involvement and prognostic factors;Aspectos sistémicos y factores pronósticos

Archivos de Bronconeumologia

Volumn 43, Issue SUPPL. 3, 2007, Pages 25-34

  Casanova Macario, Ciro ^a   Tajes, Juan Pablo De Torres ^b   De Oca, Maria Montes ^c  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

EPOC; Prognostic; Systemic

Indexed keywords

CYTOKINE; FIBRINOGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATORY DISEASE; OXYGEN TENSION; PHENOTYPIC VARIATION; PROGNOSIS; REVIEW; SURVIVAL; SYSTEMIC DISEASE; TOTAL LUNG CAPACITY;

EID: 38349136486     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/s0300-2896(07)71182-1     Document Type: Review

References (86)

1. Pauwels R, Buist SA, Calverley P, Jenkins C, Hurd S. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for chronic obstructive pulmonary disease (GOLD). Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76. Update 2006.
2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.
3. Peces-Barba G, Agusti A, Barberá JA, et al. Enfermedad Pulmonar Obstructiva Crónica. Normativa SEPAR-ALAT. Arch Bronconeumol. 2007. En prensa.
4. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28:1245-57.
5. Agustí A. Systemic effects of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2005;2:367-70.
6. Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L, et al. The nature of small-airway obstruction in chornic obstructive pulmonary disase. N Engl J Med. 2004;350:2645-53.
7. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-80.
8. Turato G, Di Stefano A, Maestrelli P, Mapp CE, Ruggieri MP, Roggeri A, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med. 1995;152:1262-7.
9. Oudijk EJ, Nijhuis EH, Zwank MD, Van de Graaf EA, Mager HJ, et al. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax. 2005;60:538-44.
10. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002;166:1218-24.
11. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819-24.
12. Cosio BG, Agusti A. Autoinmunidad en la EPOC. Arch Bronconeumol 2005;41 Supl 5:10-4.
13. Yanbaeva DG, Dentener MA, Creutzberg EC, Wouters EF. Systemic inflammation in COPD: is genetic susceptibility a key factor? COPD. 2006;3:51-61.
14. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61:23-8.
15. De Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27:902-7.
16. Hurst JR, Donaldson GC, Pererea WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867-74.
17. Sinn DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760-5.
18. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006;130:326-33.
19. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive Protein as a Predictor of Prognosis in COPD. Am J Respir Crit Care Med. 2007;175:250-5.
20. Hersh CP, Miller DT, Kwiatkowski DJ, Silverman EK. Genetic determinants of C-reactive protein in COPD. Eur Respir J. 2006;28:1156-62.
21. Van Helvoort HA, Heijdra YF, Thijs HM, Vina J, Wanten GJ, Dekhuijzen PN. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc. 2006;38:1543-52.
22. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126:926-34.
23. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127:1952-9.
24. Friedman GD, Klatsky AL, Siegelaub AB. Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1976;294:1071-5.
25. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63-70.
26. Verma S, Yeh ET. C-reactive protein and atherothrombosis - beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol. 2003;285:1253-6.
27. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996;153:976-80.
28. Toral J, Ortega F, Cejudo P, Elias T, Sanchez H, Montemayor T. Fuerza de los músculos periféricos en pacientes con EPOC estable: correlación con parámetros funcionales respiratorios y de calidad de vida. Arch Bronconeumol. 1999;35:117-21.
29. Montes de Oca M, Torres SH, Gonzalez Y, Romero E, Hernández N, Mata A, Tálamo C. Peripheral muscle composition and health status in patients with COPD. Respiratory Medicine. 2006;100:1800-6.
30. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J. 1997;10:417-23.
31. Marquis K, Debigaré R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:809-13.
32. Schols A, Slangen J, Volovics L, Wouters E. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791-7.
33. Whittom F, Jobin J, Simard P, Leblanc P, Simard C, Bernard S, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in COPD patients. Med Sci Sports Exerc. 1998;30:1467-74.
34. Jobin J, Maltais F, Doyon J, Leblanc P, Simard P, Simard A, et al. Chronic obstructive pulmonary disease: capillarity and fiber-type characteristics of skeletal muscle. J Cardiopulm Rehaz. 1998;18: 432-7.
35. Gosker H, Engelen M, Van Maceren H, Van Dijk P, Van der Vusse G, Wouters E, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr. 2002;76:113-9.
36. Jakobsson P, Jorfeldt L, Heriksson J. Metabolic enzyme activity in the quadriceps femoris muscle in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:374-7.
37. Maltais F, Simard A, Simard C, Jobin J, Desgagnes P, Leblanc P. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in COPD. Am J Respir Crit Care Med. 1996;153:288-93.
38. Maltais F, LeBlanc P, Simard C, Jobin J, Berube C, Bruneau J, et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:442-7.
39. Montes de Oca M, Torres S, Gonzalez Y, Romero E, Hernández N, Tálamo C. Cambios en la tolerancia al ejercicio, calidad de vida y características de los músculos periféricos después de 6 semanas de entrenamiento en pacientes con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2005;41:413-8.
40. Eid A, Ionescu A, Nixon L, Lewis-Jenkins V, Matthews S, Griffiths T, et al. Inflamatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1414-8.
41. Di Francia M, Barbier D, Mege J, Orejek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;150:1453-5.
42. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax. 2004;59:483-7.
43. Montes de Oca M, Torres SH, De Sanctis J, Mata A, Hernández N, Tálamo C. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J. 2005;26:390-7.
44. Vermeeren M, Creutzberg E, Schols A, Postma D, Pieters W, Roldaan A, et al; on behalf of the COSMIC Study Group. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med. 2006;100:1349-55.
45. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006;173:79-83.
46. Schols A, Soeters P, Dingemans A, Mostert R, Frantzen P, Wouters E. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151-6.
47. John M, Hoernig S, Doehner W, Okonko DD, Witt C, Anker SD. Anemia and inflammation in COPD. Chest. 2005;127:825-9.
48. Chambellan A, Chailleux E, Similowski T, and the ANTADIR observatory group. Prognostic value of the hematocrit in patients with severe COPD receiving longterm oxygen therapy. Chest. 2005;128:1201-8.
49. Similowski T, Agusti A, MacNee W, Schonhofer B. The potential impact of anaemia of chronic disease in COPD. Eur Respir J. 2006;27:390-6.
50. Martinez FJ, Foster G, Curtis JL, et al. NETT Research Group. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med. 2006;173:1326-34.
51. Cote C, Zilberger MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29:923-9.
52. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease-A cross sectional study. Respir Med. 2007;101:177-85.
53. Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease Am J Respir Crit Care Med.2004;170:1286-93.
54. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depresión. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:201-17.
55. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Enq P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167:60-7.
56. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645-8.
57. Anthonisen NR, Wright EC, Hodgkin JE, the IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986;133:14-20.
58. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233-9.
59. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005;60:992-7.
60. Celli BR, Cote C, Marin JM, Casanova C, Montes de Oca M, Mendez R, et al. The Body Mass Index, Airflow Obstruction, Dyspnea, Exercise Performance (BODE) Index in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2004;350:1005-12.
61. García-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Antó JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58:100-5.
62. García-Aymerich J, Lange P, Benet M, Schnohr T, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population-based cohort study. Thorax. 2006;61:772-8.
63. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Goselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:972-7.
64. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23:28-33.
65. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factor related to mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:544-9.
66. Casanova C, Cote CG, Marín JM, De Torres JP, Aguirre-Jaíme A, Mendez R, et al. The six-minute walk distance: long-term follow up in patients with COPD. Eur Respir J. 2007;29:535-40.
67. Takigawa N, Tada A, Soda R, et al. Distance and oxygen desaturation in 6-min walk test predit prognosis in COPD patients. Resp Med. 2007;101:561-7.
68. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-22.
69. Soler JJ, Martinez-Garcia MA, Roman P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925-31.
70. Chu CM, Chan VL, Lin AWN, Wong IW, Leung WS, Lai CK. Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. Thorax. 2004;59:1020-5.
71. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med. 1996;154:959-67.
72. Nocturnal Oxygen Therapy Trial Group. Continuos or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93:391-8.
73. Medical Research Council. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet. 1981;1:681-6.
74. Chailleux E, Fauroux B, Binet F, Dautzenberg B, Polu JM. Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation. Chest. 1996;106:741-9.
75. Casanova C, Cote C, De Torres JP, Aguirre-Jaime A, Marín JM, Pinto-Plata V, et al. The inspiratory to total lung capacity ratio predicts mortality in patients with COPD. Am J Respir Crit Care Med. 2005;171:591-7.
76. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1395-9.
77. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:189-94.
78. Oswal-Mammosser M, Weitzenblun E, Quoix E, Moser G, Chaouat A, Charpentier C. Prognostic factors in COPD patients receiving long-term oxygen therapy. Chest. 1995;107:1193-8.
79. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434-40.
80. Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Félez M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:680-5.
81. Incalzi RA, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality in patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-800.
82. De Torres JP, Casanova C, Montejo de Garcini A, Aguirre-Jaíme A, Celli BR. COPD heterogeneity: gender differences in the multidimensional BODE index. Journal of COPD. 2007. En prensa.
83. Cote CG, Dordelly LJ, Celli BR, Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007;131:696-704.
84. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J. 2005;26:630-36.
85. Imfeld S, Bloch KE, Weder W, Russi EW. The BODE index after lung volume reduction surgery correlates with survival. Chest. 2006;129:873-8.
86. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745-55.